Price
Target price
€69.50
€69.50
-1.320%
-0.92
-1.320%
€105.83
19.06.26 / Tradegate
WKN: 529882 / Symbol: CORT / Name: Corcept / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corcept Therapeutics Inc. Stock
We can see a decrease in the price for Corcept Therapeutics Inc.. Compared to yesterday it has lost -€0.920 (-1.320%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 105 € there is a hugely positive potential of 51.08% for Corcept Therapeutics Inc. compared to the current price of 69.5 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -1.320% | -3.041% | 38.612% | 13.192% | 1.638% | 227.830% | 265.789% |
| Rockwell Medical Inc. | -2.650% | 1.852% | -18.519% | -31.078% | -18.699% | -85.602% | -93.007% |
| Pacira Pharmaceuticals | 0.000% | -2.030% | 1.047% | -6.311% | -10.648% | -47.268% | -60.124% |
| Twist Bioscience Corp | -1.230% | 15.710% | 78.486% | 146.233% | 173.465% | 355.230% | -18.632% |
Comments
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $110.00 to $135.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
News
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately